BioScrip Inc (BIOS) Receives $5.15 Consensus Target Price from Brokerages

Share on StockTwits

Shares of BioScrip Inc (NASDAQ:BIOS) have been given a consensus recommendation of “Buy” by the eight analysts that are currently covering the firm, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation and six have issued a buy recommendation on the company. The average twelve-month target price among analysts that have updated their coverage on the stock in the last year is $5.15.

Several analysts have issued reports on the stock. Zacks Investment Research cut shares of BioScrip from a “hold” rating to a “sell” rating in a research note on Thursday, January 3rd. BidaskClub upgraded shares of BioScrip from a “buy” rating to a “strong-buy” rating in a research report on Friday, September 21st. TheStreet upgraded shares of BioScrip from a “d+” rating to a “c-” rating in a research report on Monday, November 26th. Barrington Research restated a “buy” rating and set a $4.00 price objective on shares of BioScrip in a research report on Friday, October 5th. Finally, Canaccord Genuity started coverage on shares of BioScrip in a research report on Wednesday, December 12th. They set a “buy” rating and a $5.00 price objective on the stock.

Several institutional investors have recently bought and sold shares of the company. Venor Capital Management LP raised its position in shares of BioScrip by 0.3% during the 3rd quarter. Venor Capital Management LP now owns 14,475,087 shares of the company’s stock valued at $44,873,000 after buying an additional 50,000 shares in the last quarter. BlackRock Inc. raised its position in shares of BioScrip by 0.4% during the 3rd quarter. BlackRock Inc. now owns 7,616,244 shares of the company’s stock valued at $23,610,000 after buying an additional 31,899 shares in the last quarter. Vanguard Group Inc grew its holdings in shares of BioScrip by 0.5% during the 3rd quarter. Vanguard Group Inc now owns 5,987,679 shares of the company’s stock valued at $18,562,000 after purchasing an additional 27,904 shares during the last quarter. Vanguard Group Inc. grew its holdings in shares of BioScrip by 0.5% during the 3rd quarter. Vanguard Group Inc. now owns 5,987,679 shares of the company’s stock valued at $18,562,000 after purchasing an additional 27,904 shares during the last quarter. Finally, FMR LLC grew its holdings in shares of BioScrip by 3.3% during the 2nd quarter. FMR LLC now owns 5,593,200 shares of the company’s stock valued at $16,388,000 after purchasing an additional 179,700 shares during the last quarter. Hedge funds and other institutional investors own 82.09% of the company’s stock.

NASDAQ BIOS traded up $0.01 on Tuesday, hitting $3.87. The stock had a trading volume of 23,333 shares, compared to its average volume of 926,027. BioScrip has a 52-week low of $2.31 and a 52-week high of $4.14. The stock has a market capitalization of $510.88 million, a PE ratio of -8.73 and a beta of 0.61.

BioScrip (NASDAQ:BIOS) last posted its earnings results on Tuesday, November 6th. The company reported ($0.09) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.07) by ($0.02). The business had revenue of $181.00 million for the quarter, compared to analyst estimates of $171.35 million. During the same quarter in the previous year, the company earned ($0.12) EPS. BioScrip’s quarterly revenue was down 8.9% on a year-over-year basis. On average, analysts forecast that BioScrip will post -0.33 EPS for the current fiscal year.

BioScrip Company Profile

BioScrip, Inc provides infusion solutions in the United States. It engages in the preparation, delivery, administration, and clinical monitoring of pharmaceutical treatments that are administered to a patient through intravenous, subcutaneous, intramuscular, intra-spinal, and enteral methods. The company is primarily involved in the intravenous administration of medications to treat a range of acute and chronic conditions, such as infections, nutritional deficiencies, immunologic and neurologic disorders, cancer, pain, and palliative care.

Featured Article: Do stock splits help investors?

Analyst Recommendations for BioScrip (NASDAQ:BIOS)

Receive News & Ratings for BioScrip Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioScrip and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply